- Home
- STOK vs NXP Comparison
STOK vs NXP Comparison
Compare STOK & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- NXP
- Stock Information
- Founded
- STOK 2014
- NXP 1992
- Country
- STOK United States
- NXP United States
- Employees
- STOK N/A
- NXP N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- NXP Trusts Except Educational Religious and Charitable
- Sector
- STOK Health Care
- NXP Finance
- Exchange
- STOK Nasdaq
- NXP Nasdaq
- Market Cap
- STOK 721.4M
- NXP 715.7M
- IPO Year
- STOK 2019
- NXP N/A
- Fundamental
- Price
- STOK $12.03
- NXP $14.55
- Analyst Decision
- STOK Strong Buy
- NXP
- Analyst Count
- STOK 7
- NXP 0
- Target Price
- STOK $21.40
- NXP N/A
- AVG Volume (30 Days)
- STOK 405.8K
- NXP 70.0K
- Earning Date
- STOK 11-05-2024
- NXP 01-01-0001
- Dividend Yield
- STOK N/A
- NXP 4.04%
- EPS Growth
- STOK N/A
- NXP N/A
- EPS
- STOK N/A
- NXP 0.54
- Revenue
- STOK $16,742,999.00
- NXP N/A
- Revenue This Year
- STOK $91.67
- NXP N/A
- Revenue Next Year
- STOK $5.45
- NXP N/A
- P/E Ratio
- STOK N/A
- NXP $26.81
- Revenue Growth
- STOK 81.08
- NXP N/A
- 52 Week Low
- STOK $3.77
- NXP $12.91
- 52 Week High
- STOK $17.58
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- STOK 39.51
- NXP 36.80
- Support Level
- STOK $13.39
- NXP $14.55
- Resistance Level
- STOK $14.72
- NXP $14.77
- Average True Range (ATR)
- STOK 0.68
- NXP 0.16
- MACD
- STOK 0.03
- NXP -0.01
- Stochastic Oscillator
- STOK 7.24
- NXP 4.35
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.